Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients
The purpose of this trial is to study the effectiveness of the AprictyRxTM care service to improve treatment outcomes of ethnic/racial minority N.S.C.L.C. patients receiving standard of care immunotherapy, and reduce the frequency of healthcare system interactions.
Checked against the public recordLast updated May 5, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Columbia University
- Interventions being studied
- Other: Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Age≥ 18 years * Confirmed NSCLC diagnosis * Prescribed treatment with immune-checkpoint inhibitor, including in combination with chemotherapy * Ability to understand and the willingness to sign a written informed consent document * Self-identification as a member of an ethnic minority or underserved population. Exclusion Criteria: * An individual with presence of any medical, psychological, or social condition that, in the opinion of the investigator would preclude participation in this study. * Patients enrolled in other interventional clinical trials at the time of screening will be excluded.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Montefiore Health CenterNew York, New York
- Mount Sinai School of MedicineNew York, New York
- NYU Medical CenterNew York, New York
- Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer CenterNew York, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 5, 2026. Always confirm current availability with the study team.